These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23707991)

  • 21. New targets of high-density lipoprotein therapy.
    Nicholls SJ; Nissen SE
    Curr Opin Lipidol; 2007 Aug; 18(4):421-6. PubMed ID: 17620859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
    Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA
    Int J Cardiol; 2015 Nov; 199():204-12. PubMed ID: 26204569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
    Meyers CD; Kashyap ML
    Curr Opin Cardiol; 2004 Jul; 19(4):366-73. PubMed ID: 15218398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport.
    Duffy D; Rader DJ
    Curr Opin Cardiol; 2005 Jul; 20(4):301-6. PubMed ID: 15956827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advances in the study of anti-atherosclerosis drugs].
    Guo CB; Li S
    Yao Xue Xue Bao; 2007 Mar; 42(3):231-5. PubMed ID: 17520819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-density lipoprotein/apolipoprotein A-I infusion therapy.
    Tardif JC; Heinonen T; Noble S
    Curr Atheroscler Rep; 2009 Jan; 11(1):58-63. PubMed ID: 19080729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides.
    Uehara Y; Chiesa G; Saku K
    Circ J; 2015; 79(12):2523-8. PubMed ID: 26548857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
    Clark RW
    Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging strategies for increasing high-density lipoprotein.
    Forrester JS; Shah PK
    Am J Cardiol; 2006 Dec; 98(11):1542-9. PubMed ID: 17126667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
    Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
    Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
    Schaefer EJ; Asztalos BF
    Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-density lipoprotein-raising strategies: update 2010.
    Spillmann F; Schultheiss HP; Tschöpe C; Van Linthout S
    Curr Pharm Des; 2010 May; 16(13):1517-30. PubMed ID: 20196737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HDL cholesterol: all hope is not lost after the torcetrapib setback--emerging therapeutic strategies on the horizon.
    Verma N; Figueredo VM
    Am J Ther; 2014; 21(3):222-32. PubMed ID: 22967983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.
    Toth PP; Davidson MH
    Curr Opin Cardiol; 2004 Jul; 19(4):374-9. PubMed ID: 15218399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is raising HDL a futile strategy for atheroprotection?
    Joy T; Hegele RA
    Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The promise of apolipoprotein A-I mimetics.
    Mendez AJ
    Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):171-6. PubMed ID: 20125002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.